Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Mouse Model for Neurofibromatosis

By Biotechdaily staff writers
Posted on 31 Dec 2002
Researchers have found that inactivation of the NF1 gene, which codes for neurofibromin, a protein that suppresses the ras oncogene, causes defects in the development of both the neural crest and of cardiovascular tissues. More...
These findings were published December 9, 2002, in the online edition of Nature Genetics.

Inactivation of NF1, which occurs in about 1 in 4000 births, causes neurofibromatosis type 1 (NF1) or von Recklinghausen neurofibromatosis, which are characterized by benign and malignant tumors. By not inactivating the ras oncogene, this defect also results in the overproduction of the NFATc1 protein, which is related to heart valve development.

Previously it had not been possible to produce a mouse model for this disease because developmental defects in the cardiovascular system prevented the mouse embryos from reaching full term. To circumvent this problem, researchers from the University of Pennsylvania School of Medicine (Philadelphia, USA; www.upenn.edu) engineered a mouse line that expressed the NF1 deficiency in the neural crest but not in the endothelial cells that form the developing cardiovascular system. Mice from this line survived to birth and then developed tumors typical of neurofibromatosis.

"Our work shows that the Nf1 gene blocks the ras oncogene for different purposes in the different cell types,” explained Dr. Jonathan A. Epstein, associate professor in the cardiovascular division of the University of Pennsylvania department of medicine. "In endothelial cells, we see a possibility to mitigate some of the harm done by the loss of Nf1 by blocking the excessive amounts of NFATc1 protein. The more we learn about the mechanisms behind type 1 Neurofibromatosis, the better our options for treating the disease.”



Related Links:
University of Pennsylvania

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.